RECEPTOR MEDIATED ENDOCYTOSIS TYPE MRI CONTRAST AGENTS
    1.
    发明申请
    RECEPTOR MEDIATED ENDOCYTOSIS TYPE MRI CONTRAST AGENTS 审中-公开
    受体介导的内分泌型MRI对比剂

    公开(公告)号:WO1990001295A1

    公开(公告)日:1990-02-22

    申请号:PCT/US1989003352

    申请日:1989-08-03

    Abstract: Magnetic resonance (MR) contrast agents are described whose in vivo biodistribution is based upon the ability of certain cells to recognize and internalize the MR contrast agents of the present invention, via receptor mediated endocytosis. The RME-type MR contrast agents are comprised of biodegradable superparamagnetic metal oxides associated with macromolecular species including serum proteins, hormones, asialoglycoproteins, galactose-terminal species, polysaccharides, arabinogalactan, or conjugates of these molecules with other polymeric substances such as a poly(organosilane) and dextran. An MR contrast agent prepared from biodegradable superparamagnetic iron oxide and asialofetuin, for example, arabinogalactan, is selectively localized in the hepatocytes of the liver with no significant accumulation in the spleen. The contrast agents provide an enhanced MR image and valuable information regarding the functional or metabolic state of the organ or tissue under examination.

    Abstract translation: 描述了磁共振(MR)造影剂,其体内生物分布基于某些细胞通过受体介导的胞吞作用来识别和内化本发明的MR造影剂的能力。 RME型MR造影剂由与大分子物质相关的可生物降解的超顺磁性金属氧化物组成,包括血清蛋白,激素,去唾液酸糖蛋白,半乳糖末端物质,多糖,阿拉伯半乳聚糖或这些分子与其他聚合物质的共轭物,如聚(有机硅烷 )和葡聚糖。 由可生物降解的超顺磁性氧化铁和脱唾液酸蛋白(例如阿拉伯半乳聚糖)制备的MR造影剂选择性地定位在肝脏的肝细胞中,在脾脏中没有显着的积累。 造影剂提供增强的MR图像和关于被检查的器官或组织的功能或代谢状态的有价值的信息。

Patent Agency Ranking